Glaukos Stock Forecast, Price & News

Glaukos (NYSE:GKOS) Frequently Asked Questions

Is Glaukos a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos or view top-rated stocks.

What stocks does MarketBeat like better than Glaukos?

Wall Street analysts have given Glaukos a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Glaukos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Glaukos?

Glaukos saw a decrease in short interest in August. As of August 13th, there was short interest totaling 2,030,000 shares, a decrease of 25.6% from the July 29th total of 2,730,000 shares. Based on an average trading volume of 559,400 shares, the short-interest ratio is currently 3.6 days. Currently, 4.6% of the company's stock are sold short.
View Glaukos' Short Interest.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Glaukos.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) posted its quarterly earnings results on Thursday, August, 5th. The medical instruments supplier reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.13. The medical instruments supplier earned $78.09 million during the quarter, compared to analyst estimates of $71 million. Glaukos had a negative trailing twelve-month return on equity of 3.13% and a negative net margin of 21.24%.
View Glaukos' earnings history.

How has Glaukos' stock price been impacted by Coronavirus (COVID-19)?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GKOS shares have increased by 29.3% and is now trading at $49.97.
View which stocks have been most impacted by COVID-19.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $285 million-$290 million, compared to the consensus revenue estimate of $296.24 million.

What price target have analysts set for GKOS?

8 analysts have issued 1-year price objectives for Glaukos' shares. Their forecasts range from $34.00 to $105.00. On average, they expect Glaukos' share price to reach $57.38 in the next twelve months. This suggests a possible upside of 14.8% from the stock's current price.
View analysts' price targets for Glaukos or view top-rated stocks among Wall Street analysts.

Who are Glaukos' key executives?

Glaukos' management team includes the following people:

• Thomas William Burns, President, Chief Executive Officer & Director
• Chris M. Calcaterra, Chief Operating Officer
• Joseph E. Gilliam, CFO, CAO & Senior VP-Corporate Development (LinkedIn Profile)
• L. Jay Katz, Chief Medical Officer
• Tomas Navratil, Senior Vice President-Research & Development

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Glaukos' key competitors?

Some companies that are related to Glaukos include Globus Medical (GMED), Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Nevro (NVRO), Merit Medical Systems (MMSI), Inari Medical (NARI), Haemonetics (HAE), The Beauty Health (SKIN), AtriCure (ATRC), NuVasive (NUVA), Axonics (AXNX) and Silk Road Medical (SILK).
View all of GKOS's competitors.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and The Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (12.51%), Baillie Gifford & Co. (12.10%), Vanguard Group Inc. (10.33%), Artisan Partners Limited Partnership (4.49%), State Street Corp (3.30%) and Macquarie Group Ltd. (2.37%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

Which major investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Baillie Gifford & Co., Federated Hermes Inc., Artisan Partners Limited Partnership, First Light Asset Management LLC, Invesco Ltd., Natixis, and Morgan Stanley. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos or view top insider-selling stocks.

Which major investors are buying Glaukos stock?

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Dimensional Fund Advisors LP, Renaissance Technologies LLC, Vanguard Group Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, and Bridgewater Associates LP.
View insider buying and selling activity for Glaukos or or view top insider-buying stocks.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $49.97.

How much money does Glaukos make?

Glaukos has a market capitalization of $2.33 billion and generates $224.96 million in revenue each year. The medical instruments supplier earns $-120,350,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does Glaukos have?

Glaukos employs 653 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

Where are Glaukos' headquarters?

Glaukos is headquartered at 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at (949) 367-9600 or via email at [email protected].